Publications by authors named "G L Dunbar"

A cardinal symptom of Parkinson's disease (PD) is motor dysfunction, including bradykinesia and tremors, which is quantified in the Unified PD Rating Scale (UPDRS). Although some medications provide palliative treatments for these motor deficits, their efficacy wanes and can produce unwanted side effects, such as dyskinesia. Deep-brain stimulation (DBS) has provided an alternative treatment strategy that can benefit many patients, but optimal target structures for DBS and its long-term efficacy are not fully understood.

View Article and Find Full Text PDF

Glioblastoma (GB) is a cancerous brain tumor that originates from glial cells and leads to thousands of deaths each year and a five-year survival of only 6.8 %. Treatments for GB include surgery, chemotherapy, radiation, and immunotherapy.

View Article and Find Full Text PDF

Gene therapy is an important tool for treating fetal diseases that allows for the delivery and integration of therapeutic genes into the genome of cells carrying mutations. Nanomolecules, like PAMAM dendrimers, have recently come into wider use for carrying vectors as they have several advantages over viral vectors. Namely, (1) tunable size and surface chemistry, (2) uniform size, (3) the ability to target specific tissues, and (4) the ability to carry large biomolecules and drugs.

View Article and Find Full Text PDF

Early stages of Huntington's disease (HD) before the onset of motor and cognitive symptoms are characterized by imbalanced excitatory and inhibitory output from the cortex to striatal and subcortical structures. The window before the onset of symptoms presents an opportunity to adjust the firing rate within microcircuits with the goal of restoring the impaired E/I balance, thereby preventing or slowing down disease progression. Here, we investigated the effect of presymptomatic cell-type specific manipulation of activity of pyramidal neurons and parvalbumin interneurons in the M1 motor cortex on disease progression in the R6/2 HD mouse model.

View Article and Find Full Text PDF
Article Synopsis
  • PAMAM dendrimers, particularly the generation 4 (G4) version with a fully amine surface, are highly toxic to cells, prompting researchers to modify them for better biocompatibility by introducing neutral hydroxyl groups.
  • The modified G4-90/10 dendrimers, with a surface changing to 10% amine and 90% hydroxyl, show less toxicity and effective cellular uptake in various cell types, including neurons and stem cells.
  • Studies demonstrate that these dendrimers migrate within the brain after injection, with the G4 variety exhibiting more extensive movement patterns compared to G1 dendrimers, particularly in the anterior, posterior, and lateral directions, along with unique projections to cortical areas.
View Article and Find Full Text PDF